These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 32079384)

  • 1. The Prognostic Value of
    Arslan E; Aksoy T; Gürsu RU; Dursun N; Çakar E; Çermik TF
    Mol Imaging Radionucl Ther; 2020 Feb; 29(1):17-24. PubMed ID: 32079384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Significance and Prognostic Value of the Maximum Standardized Uptake Value of
    Yin YX; Xie MZ; Liang XQ; Ye ML; Li JL; Hu BL
    Front Oncol; 2021; 11():741612. PubMed ID: 34956868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of maximum standardized uptake value measured by pretreatment 18F-FDG PET/CT in locally advanced head and neck squamous cell carcinoma.
    Cacicedo J; Fernandez I; Del Hoyo O; Navarro A; Gomez-Iturriaga A; Pijoan JI; Martinez-Indart L; Escudero J; Gomez-Suarez J; de Zarate RO; Perez JF; Bilbao P; Rades D
    Clin Transl Oncol; 2017 Nov; 19(11):1337-1349. PubMed ID: 28540535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship Between 18F-FDG PET/CT Scans and KRAS Mutations in Metastatic Colorectal Cancer.
    Kawada K; Toda K; Nakamoto Y; Iwamoto M; Hatano E; Chen F; Hasegawa S; Togashi K; Date H; Uemoto S; Sakai Y
    J Nucl Med; 2015 Sep; 56(9):1322-7. PubMed ID: 26135109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of association between KRAS mutations and 18F-FDG PET/CT in Caucasian metastatic colorectal cancer patients.
    Krikelis D; Skoura E; Kotoula V; Rondogianni P; Pianou N; Samartzis A; Xanthakis I; Fountzilas G; Datseris IE
    Anticancer Res; 2014 May; 34(5):2571-9. PubMed ID: 24778079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic Characteristics and Diagnostic Contribution of
    Arslan E; Aksoy T; Gündoğan C; Şen Ç; Yılmaz Tatar S; Dursun N; Çermik TF
    Mol Imaging Radionucl Ther; 2020 Feb; 29(1):25-32. PubMed ID: 32079385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of 18F-FDG PET/CT in evaluating molecular subtypes and clinicopathological features of primary breast cancer.
    Arslan E; Çermik TF; Trabulus FDC; Talu ECK; Başaran Ş
    Nucl Med Commun; 2018 Jul; 39(7):680-690. PubMed ID: 29893750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 18F-FDG PET/CT findings in endometrial cancer patients: the correlation between SUVmax and clinicopathologic features.
    Boonya-ussadorn T; Choi WH; Hyun J; Kim SH; Chung SK; Yoo IeR
    J Med Assoc Thai; 2014 Feb; 97 Suppl 2():S115-22. PubMed ID: 25518184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlations among KRAS Mutation, Microsatellite Instability, and 18F-FDG Uptake in Colon Cancer.
    Lee SS; Choi SJ; Park JS
    Asian Pac J Cancer Prev; 2022 Oct; 23(10):3501-3506. PubMed ID: 36308376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship between clinical and pathological findings and FDG - PET uptake in metastatic colorectal cancers.
    Kurt İnci B; Gürler F; Sütcüoğlu O; Tahtacı G; Üner A; Özet A; Günel N; Yazıcı O
    Indian J Cancer; 2024 Mar; ():. PubMed ID: 38451840
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Wu X; Huang Y; Li Y; Wang Q; Wang H; Jiang L
    Ann Nucl Med; 2019 Sep; 33(9):647-656. PubMed ID: 31165974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between KRAS mutation and
    Cho A; Jo K; Hwang SH; Lee N; Jung M; Yun M; Hwang HS
    Abdom Radiol (NY); 2017 Jun; 42(6):1621-1626. PubMed ID: 28161825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between KRAS mutations and dual time point
    Mao W; Zhou J; Zhang H; Qiu L; Tan H; Hu Y; Shi H
    Abdom Radiol (NY); 2019 Jun; 44(6):2059-2066. PubMed ID: 30143816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The value of
    Oner AO; Budak ES; Yıldırım S; Aydın F; Sezer C
    Hell J Nucl Med; 2017; 20(2):160-165. PubMed ID: 28697193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymph node standardized uptake values at pre-treatment
    Jeong Y; Baek S; Park JW; Joo JH; Kim JS; Lee SW
    Br J Radiol; 2017 Mar; 90(1071):20160239. PubMed ID: 28008776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PIK3CA Mutational Status Is Associated with High Glycolytic Activity in ER+/HER2- Early Invasive Breast Cancer: a Molecular Imaging Study Using [
    Magometschnigg H; Pinker K; Helbich T; Brandstetter A; Rudas M; Nakuz T; Baltzer P; Wadsak W; Hacker M; Weber M; Dubsky P; Filipits M
    Mol Imaging Biol; 2019 Oct; 21(5):991-1002. PubMed ID: 30652258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
    Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
    Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A New Perspective on the Effectiveness of FDG PET/CT in Predicting KRAS Mutation in Colon Cancer Cases.
    Tamer F; Yararbas U
    Cancer Biother Radiopharm; 2024 Nov; 39(9):664-672. PubMed ID: 38726607
    [No Abstract]   [Full Text] [Related]  

  • 20. Correlation between PET/CT parameters and KRAS expression in colorectal cancer.
    Chen SW; Chiang HC; Chen WT; Hsieh TC; Yen KY; Chiang SF; Kao CH
    Clin Nucl Med; 2014 Aug; 39(8):685-9. PubMed ID: 24978328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.